Get In Touch

Rise in the Prescription of Combination Therapies for AAT Deficiency Stimulates High Growth in Alpha 1 Antitrypsin Deficiency Treatment Market

Research analysts at Transparency Market Research had evaluated the global alpha 1 antitrypsin deficiency treatment market at US$ 1.4 billion in the year of 2018 i.e. the beginning of the forecast period. They also project that the global alpha 1 antitrypsin deficiency treatment market will expand at a healthy CAGR of 10.1 % over the forecast period of 2019 to 2027.

High incidence rate and rising prevalence of various respiratory diseases is the most crucial driver for the advancement of the global alpha 1 antitrypsin deficiency treatment market. Moreover, rising awareness regarding AAT deficiency along with rise in the prescription of combination therapies, and growing initiatives by governments across the world aiming at increasing plasma and blood products may fuel the growth in the global alpha 1 antitrypsin deficiency treatment market in coming years. However, high cost of therapy, lower diagnosis rate of AAT, and risk of severe side effects of treatment products such as chest pain, sinutis, back pain, and rhinorrhea can hinder the growth of the global alpha 1 antitrypsin deficiency treatment market in coming years.

Segments in the global alpha 1 antitrypsin deficiency treatment market by the type of the treatment include augmentation therapy, corticosteroids, bronchodilator, and oxygen therapy, among others. The augmentation therapy segment in the global alpha 1 antitrypsin deficiency treatment market can be further sub-segmented into aralast, zemaira, glassia, prolastin, and respreeza. Segments in the global alpha 1 antitrypsin deficiency treatment market by route of administration are parenteral, oral, and inhalations. Key end users for the products in the global alpha 1 antitrypsin deficiency treatment market include specialty clinics, pharmacies, and hospitals.

North America Dominates the Alpha 1 Antitrypsin Deficiency Treatment Market

Major regions covered in the professional analysis of the global alpha 1 antitrypsin deficiency treatment market include Europe (including the United Kingdom, Italy, Germany, Spain, France, and rest of the Europe), Latin America (including Brazil, Mexico, and rest of the Latin America), North America (including the United States and Canada), Middle East and Africa (South Africa, Gulf Cooperation Council countries, and rest of the Middle East and Africa), and Asia Pacific (including Japan, New Zealand, China, Australia, India, and rest of the Asia Pacific). Geographically, North America region lead the global alpha 1 antitrypsin deficiency treatment market in terms of revenue, owing to rising prevalence of respiratory disorders as well as enhanced diagnosis rate for AAT deficiency in the region. Another key factor motivating the growth of North America alpha 1 antitrypsin deficiency treatment market is increasing investments in research and development funding by leading regional players.

Europe region is also expected to present lucrative expansion opportunities in the global alpha 1 antitrypsin deficiency treatment market during the forecast period of 2019 to 2027. This trend can be attributed to factors such as rising elderly population that has higher risk of respiratory diseases, increasing product demand as well as rising awareness regarding the therapeutic solutions from the global alpha 1 antitrypsin deficiency treatment market, and increasing research and development activities aimed at developing novel treatments for respiratory disorders.

Players in Alpha 1 Antitrypsin Deficiency Treatment Market Engaged in Strategic Partnerships and Collaborations

Top incumbent players assessed in the market assessment of global alpha 1 antitrypsin deficiency treatment market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S.A., Grifols, S.A., CSL Behring, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Teva Pharmaceutical Industries, Ltd. the global alpha 1 antitrypsin deficiency treatment market witnesses a highly fragmented competitive landscape with a number of international players holding a large share in the global alpha 1 antitrypsin deficiency treatment market.

Leading players and manufacturers in the global alpha 1 antitrypsin deficiency treatment market are focusing their funds as well as their efforts in gaining regulatory approvals for new products and developing new products. Key strategies implemented by the players in the global alpha 1 antitrypsin deficiency treatment market include acquisitions as well as collaborative agreements with other players. For example, Kamada Ltd, opted to extend their tactical supply arrangement with Takeda Pharmaceutical Company in order to streamline their production of GLASSIA Alpha 1 Proteinase inhibitor in September of 2019.

The global Alpha 1 Antitrypsin Deficiency Treatment market has been segmented as follows:

  • Global Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment Type
    • Augmentation Therapy
      • Aralast
      • Prolastin
      • Zamaira/ Respreeza,
      • Glassia
    • Bronchodilator
    • Corticosteroids
    • Oxygen Therapy
    • Others
  • Global Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration
    • Parenteral
    • Inhalation
    • Oral
  • Global Alpha 1 Antitrypsin Deficiency Treatment Market, by End-user
    • Hospitals
    • Specialty Clinics
    • Pharmacies
  • Global Alpha 1 Antitrypsin Deficiency Treatment Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC